To date, only two cost-effectiveness studies have assessed the use of immune checkpoint inhibitors as first-line treatments for HER2-negative advanced G/GEJ adenocarcinoma within the Chinese healthcare system. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.